Por favor, use este identificador para citar o enlazar este ítem:
https://hdl.handle.net/11000/31049
Registro completo de metadatos
Campo DC | Valor | Lengua/Idioma |
---|---|---|
dc.contributor.author | Moreno-Pérez, Oscar | - |
dc.contributor.author | LEON-RAMIREZ, JOSE-MANUEL | - |
dc.contributor.author | Fuertes Kenneally, Laura | - |
dc.contributor.author | Perdiguero, Miguel | - |
dc.contributor.author | Garcia-Navarro, Mar | - |
dc.contributor.author | Ruiz-Torregrosa, Paloma | - |
dc.contributor.author | Boix, Vicente | - |
dc.contributor.author | Gil, Joan | - |
dc.contributor.author | Merino, Esperanza | - |
dc.contributor.author | On behalf of COVID19-ALC Research Group | - |
dc.contributor.other | Departamentos de la UMH::Medicina Clínica | es_ES |
dc.date.accessioned | 2024-02-05T11:51:29Z | - |
dc.date.available | 2024-02-05T11:51:29Z | - |
dc.date.created | 2020 | - |
dc.identifier.citation | International Journal of Infectious Diseases . 2020 Nov:100:449-454 | es_ES |
dc.identifier.issn | 1878-3511 | - |
dc.identifier.uri | https://hdl.handle.net/11000/31049 | - |
dc.description.abstract | Objectives: Serum levels of potassium (K+) appear to be significantly lower in severe cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the clinical significance of this is unknown. The objective was to investigate whether hypokalemia acts as a biomarker of severity in coronavirus disease 2019 (COVID-19) pneumonia and is associated with major clinical outcomes.Methods: A retrospective cohort study of inpatients with COVID-19 pneumonia (March 3 to May 2, 2020) was performed. Patients were categorized according to nadir levels of K+ in the first 72 h of admission: hypokalemia (K+ ≤3.5 mmol/l) and normokalemia (K+ >3.5 mmol/l). The main outcomes were all-cause mortality and the need for invasive mechanical ventilation (IMV); these were analyzed by multiple logistic regression (odds ratio (OR), 95% confidence interval (CI)).Results: Three hundred and six patients were enrolled. Ninety-four patients (30.7%) had hypokalemia and these patients showed significantly higher comorbidity (Charlson comorbidity index ≥3, 30.0% vs 16.3%; p = 0.02) and CURB65 scores (median (interquartile range): 1.5 (0.0-3.0) vs 1.0 (0.0-2.0); p = 0.04), as well as higher levels of some inflammatory parameters at baseline. After adjustment for confounders, hypokalemia was independently associated with requiring IMV during the admission (OR 8.98, 95% CI 2.54-31.74). Mortality was 15.0% (n = 46) and was not influenced by low K+. Hypokalemia was associated with longer hospital and ICU stays.Conclusions: Hypokalemia is prevalent in patients with COVID-19 pneumonia. Hypokalemia is an independent predictor of IMV requirement and seems to be a sensitive biomarker of severe progression of COVID-19. | es_ES |
dc.format | application/pdf | es_ES |
dc.format.extent | 6 | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Elsevier | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | COVID19 pneumonia | es_ES |
dc.subject | Cohort study | es_ES |
dc.subject | Hypokalemia | es_ES |
dc.subject | Mechanical ventilation | es_ES |
dc.subject | Mortality | es_ES |
dc.subject.other | CDU::6 - Ciencias aplicadas::61 - Medicina::616 - Patología. Medicina clínica. Oncología | es_ES |
dc.title | Hypokalemia as a sensitive biomarker of disease severity and the requirement for invasive mechanical ventilation requirement in COVID-19 pneumonia: A case series of 306 Mediterranean patients | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.relation.publisherversion | https://doi.org/10.1016/j.ijid.2020.09.033 | es_ES |
![Vista previa](/retrieve/a8c6ffbe-6548-45ca-b032-35b539a4adaf/Hypokalemia%20as%20a%20sensitive%20biomarker%20of%20disease%20severity%20and%20the.pdf.jpg)
Ver/Abrir:
Hypokalemia as a sensitive biomarker of disease severity and the.pdf
460,38 kB
Adobe PDF
Compartir:
La licencia se describe como: Atribución-NonComercial-NoDerivada 4.0 Internacional.